18213-75-7

Basic information

• Product Name: 5-Amino-1-methylpyrazole-4-carboxamide
• Synonyms: 5-AMINO-1-METHYLPYRAZOLE-4-CARBOXAMIDE;5-AMINO-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE;5-AMINO-1-METHYL-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE;BUTTPARK 94\04-11;5-Amino-1-methylpyrazole-4-carboxamide, tech;5-Amino-1-methyl-1h-pyrazole-4-carboxamide, tech;1H-Pyrazole-4-carboxamide,5-amino-1-methyl-(9CI);5-Amino-1,3-dimethyl-1H-pyrazole-4-carboxamide
• CAS NO: 18213-75-7
• Molecular Formula: C₅H₈N₄O
• Molecular Weight: 140.14
• EINECS: 200-258-5
• Product Categories: AMIDE;Miscellaneous
• Mol File: 18213-75-7.mol
• Article Data: 4

Chemical Properties

• Melting Point: 224-226°C
• Boiling Point: 355.1 °C at 760 mmHg
• Flash Point: 168.6 °C
• Appearance: /
• Density: 1.56 g/cm³
• Vapor Pressure: 3.2E-05mmHg at 25°C
• Refractive Index: 1.695
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 5-Amino-1-methylpyrazole-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-1-methylpyrazole-4-carboxamide(18213-75-7)
• EPA Substance Registry System: 5-Amino-1-methylpyrazole-4-carboxamide(18213-75-7)

Safety Data

• Hazard Codes: Xi,T
• Statements: 36/37/38-25
• Safety Statements: 26-36/37/39-24/25-22-45
• RIDADR: UN 2811 6.1 / PGIII
• HazardClass: IRRITANT
• Hazardous Substances Data: 18213-75-7(Hazardous Substances Data)

Usage

General Description

5-Amino-1-methylpyrazole-4-carboxamide, also known as 5-AMP-4C, is a chemical compound with the molecular formula C5H7N5O. It is a derivative of pyrazole and is commonly used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. 5-AMP-4C is a white solid that is soluble in water and has a molecular weight of 145.14 g/mol. It is known for its potential applications in the development of drugs and has been studied for its pharmacological properties, particularly its antimicrobial and anticancer activities. 5-Amino-1-methylpyrazole-4-carboxamide is also used as a building block for the synthesis of other important compounds in the pharmaceutical and chemical industries.

InChI:InChI=1/C5H8N4O/c1-9-4(6)3(2-8-9)5(7)10/h2H,6H2,1H3,(H2,7,10)

Upstream product

• 37858-68-7 α-Cyano-β-dimethylaminoacrylamide 
• 302-15-8 methylhydrazine sulfuric acid 
• 5334-41-8 5-amino-4-cyano-1-methylpyrazole 

Downstream Products

• 5334-27-0 1-methyl-6-thioxo-1,5,6,7-tetrahydro-pyrazolo[3,4-d]pyrimidin-4-one 
• 5401-15-0 1-Methyl-1H-pyrazolo<3,4-d>pyrimidine-4,6(5H,7H)-dione 
• 931075-55-7 6-(chloromethyl)-1-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 57121-52-5 1,6-dimethyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 98550-75-5 4-chloro-1,6-dimethyl-1H-pyrazolo[3,4-d]pyrimidine 
• 1361961-28-5 6-(difluoro-(4-fluorophenyl)methyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-ol 
• 1361960-65-7 6-(difluoro-(4-fluorophenyl)methyl)-1-methyl-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 5417-83-4 1-methyl-6-(methylsulfanyl)-1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one 
• 5334-54-3 1,5-dimethylallopurinol 
• 36274-16-5 6-phenyl-1-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 139954-48-6 6-(4-methylphenyl)-1-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 

Relevant articles and documents

COMBINATION THERAPY FOR TREATING MPS1

The application is directed to compounds of formula (I) and their salts and solvates, wherein B, R1, R2, R3, R3', R4, R4', and R5 are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., MPS1, optionally in combination with α-L-iduronidase or an analog or variant thereof, e.g., laronidase.

PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. [Fomula I]